Dialogues on AI Digital Pathology is a podcast series that looks into the role of AI in drug discovery and treatment development efforts for Nonalcoholic Steatohepatitis (NASH). Do click onto the webinars/podcasts to listen to our guest speakers, who are clinical and industry experts in the field of liver diseases. Follow/Subscribe to our Podcasts now!
Also featured in this page are the Deciphering NASH webinar series hosted by HistoIndex, as well as industry podcasts HistoIndex has participated in, such as Surfing the NASH Tsunami and Digital Pathology Today).
Date: 27 Apr 2022
We are very pleased to share with you that our webinar, Deciphering NASH: Fibrosis Dynamics in Cirrhotic Patients & Insights into Ballooned Hepatocytes Using AI, is now available for viewing...Read More
Date: 09 Mar 2022
How Can an Informed Application of Artificial Intelligence Improve Ballooned Hepatocyte Identification and Analysis in Advanced Fibrosis and Cirrhosis?Read More
Date: 09 Mar 2022
How can a reassessment of the way we analyze ballooned hepatocyte cells in clinical trials reshape drug development practices and the success rates in clinical trials?Read More
Date: 09 Mar 2022
Do the Semi-Quantitative Rules We Apply to Ballooned Hepatocyte Analysis Inherently Create Error?Read More
Date: 09 Mar 2022
What Can We Learn about the Sources of Statistical Error We Create in Ballooned Hepatocyte Analysis and How Can We Manage It Better?Read More
Date: 09 Mar 2022
Do inconsistent analyses of ballooned hepatocytes between different hepatopathologists lead to negative results in NASH Clinical Trials?Read More
Date: 09 Mar 2022
One major discussion at NASH-TAG this year was about the inconsistency in ballooned hepatocyte identification and how this inconsistency inflates screen fail rates and possibly placebo response across studies. This episode explores that issue in detail.
The episode is sponsored by HistoIndex. At the back of the episode is a discussion of how artificial intelligence-driven assistive technology can improve the consistency of ballooned hepatocyte scoring in advanced fibrosis and support the development of robust outcomes for fibrosis studies.Read More
Date: 27 Jan 2022
This episode discusses the AI-based digital pathology developed at HistoIndex. What is multiphoton technology? What is second harmonic generation (SHG)? The clinical applications HistoIndex is focusing on first is NASH – nonalcoholic steatohepatitis. What is NASH? What is the unmet need? How does it affect society? What are the diagnostic challenges?Read More
Date: 26 Oct 2021
We are very pleased to share with you that Deciphering NASH: Revealing the Unrevealed in Stain-free Biopsies, held on 7 October 2021, is now available for public viewing on HistoIndex’s YouTube channel.Read More
Date: 07 Jun 2021
We’re very happy to bring you Part 4 that will wrap up the Special Episode podcast of Dialogues on AI Digital Pathology!Read More
Date: 03 Jun 2021
Dialogues on AI Digital Pathology is releasing Part 4 of its Special Episode next week! Listen to this trailer for a snippet of our guests, KOL hepatologists and Pharma Thought...Read More
Date: 18 May 2021
It's finally here! Listen to Part 3 of our Special Episode, where our guests – KOL Hepatologists and Pharma Thought Leaders in NASH – respond to questions on how AI...Read More
Date: 13 May 2021
Our Special Episode conversation continues with our guests, KOL hepatologists and Pharma Thought Leaders in NASH! They will respond to questions from the pharma and clinical investigators on how AI...Read More
Date: 17 Mar 2021
Our guest KOL liver pathologists continue their conversation from Part 1 following the FDA Webcast, by responding to more questions by Pharma companies and clinical investigators on how AI Digital Pathology (AI-DP) can aid pathologists with precise assessment to better interpret the disease biology of NASH.
Date: 12 Mar 2021
Here's the Official Trailer for Part 2 of our Special Episode of Dialogues on AI Digital Pathology, which is coming up in a week! Listen to these sound bites from our guest KOL liver pathologists, Professor Pierre Bedossa, Professor Zachary Goodman, and Professor David Kleiner as they speak to our Moderator, Dr Nikolai Naoumov about AI digital pathology as a complementary tool for pathologists in interpreting the disease biology of NASH.Read More
Date: 09 Mar 2021
Listen to our guests, KOL liver pathologists as they discuss the recent FDA Webcast on NASH drug development and utilization of AI digital pathology as potential clinical trial endpoints.
Here’s Part 1, where the KOL liver pathologists will discuss key takeaways from the recent FDA Webcast on NASH Drug Development, and respond to questions sent in by Pharma companies and clinical investigators on potential clinical trial strategies using AI digital pathology following the Webcast.Read More
Date: 05 Mar 2021
We're commencing a two-part Special Episode of Dialogues on AI Digital Pathology!
This episode brings together our guests, Key Opinion Leaders in liver pathology, who will be speaking about the key takeaways from the recent FDA webcast on NASH Drug Development, and responding to questions from the industry on designing clinical trial strategies with AI digital pathology. Here's a Trailer of Part 1 with snippets from Professor Pierre Bedossa, Professor Zachary Goodman, and Professor David Kleiner as they speak to our Moderator, Dr Nikolai Naoumov.Read More
Date: 08 Dec 2020
In this episode*, we speak to Dr. Nikolai Naoumov, MD, PhD, FRCP, FRCPAth, FAASLD (Adviser for Clinical Research and Drug Development in Liver Diseases at Novartis, and physician-scientist and specialist in liver diseases). With his current focus on AI digital pathology in assessing liver biopsies, NASH combination therapies, HBV cure and liver fibrosis, Nikolai speaks to us on the changing landscape of drug development for NASH fuelled by advances in AI digital pathology.
*This episode concludes Season 1 of Dialogues on AI Digital Pathology, and we will be commencing our second podcast season in mid-2021. Meanwhile, the webinars series on AI Digital Pathology in both NASH preclinical studies and clinical trials will commence in the first half of 2021. We’ll keep you posted on our webinars. Do remember to hit the Subscribe or Follow buttons at the following platforms to be updated when the Podcast’s Season 2 begins!Read More
Date: 02 Dec 2020
In the upcoming episode 4 of Dialogues on AI Digital Pathology, we speak to Dr. Nikolai Naoumov, MD, PhD, FRCP, FRCPAth, FAASLD (Adviser for Clinical Research and Drug Development in Liver Diseases at Novartis). Nikolai is a physician-scientist with a professional career combining academic research, clinical care and drug development – all focused on liver diseases.
With his current work focusing on digital pathology with AI assessment of liver biopsies, NASH combination therapies, HBV cure and liver fibrosis, Nikolai shares his views about the advantages and impact of AI digital pathology in drug development efforts for NASH.Read More
Date: 03 Nov 2020
Listen to our guest, Dr. Suneil Hosmane (Executive Vice President and Global Head of Diagnostics at GENFIT), as he speaks about the role of AI digital pathology, the latest NIS4 blood-based diagnostic test by Genfit and how AI digital pathology can work with non-invasive technologies (NITs) to enhance drug development efforts in NASH clinical trials today that could ultimately transform the NASH clinical care pathway.
Date: 28 Oct 2020
[Podcast Trailer Alert - Dialogues on AI Digital Pathology]
Episode 3 is coming up real soon! Here's a sound bite from our guest, Dr. Suneil Hosmane (Executive Vice President and Global Head of Diagnostics at GENFIT), who will share his views on how AI digital pathology can work with non-invasive technologies (NITs) to enhance drug development efforts and benefit patient outcomes.
Watch out for our updates next week when Episode 3 goes Live! Do remember to Subscribe to or Follow us on Anchor, Apple Podcasts, Spotify and Google Podcasts!Read More
Date: 13 Oct 2020
In Episode 2 of Dialogues on Digital Pathology, we speak to Dr. David Kleiner, Senior Research Physician and Chief of Post-mortem Section, Laboratory of Pathology, from the Center for Cancer Research at the National Cancer Institute.
Dr. Kleiner will be sharing his views on AI digital pathology and how it can work hand-in-hand with liver pathologists to empower NASH drug development and clinical practice. During the Q&A segment, Dr. Kleiner will be joined by supporting guest, Dr. Dean Tai, Chief Scientific Officer of HistoIndex, who will provide his insights on the role of machine learning in reinforcing important diagnostic decisions for NASH.Read More
Date: 08 Oct 2020
Watch out for our upcoming episode next week with our guest, Dr. David Kleiner, Senior Research Physician and Chief of Post-mortem Section, Laboratory of Pathology, from the Center for Cancer Research at the National Cancer Institute. Dr. Kleiner will be sharing his views on AI digital pathology and how it can work hand-in-hand with liver pathologists to empower NASH drug development and clinical practice.
Date: 17 Aug 2020
In our inaugural episode of Dialogues on AI Digital Pathology, we speak to Dr Stephen Harrison (Medical Director of Pinnacle Clinical Research) on the role AI digital pathology can play in current NASH drug development.
Date: 12 Aug 2020
Welcome to Dialogues on AI Digital Pathology. In this Podcast series, we’ll be speaking to medical and industry experts, who will be sharing their thoughts on the evolving trends of AI digital pathology and its role in finding effective treatments for Nonalcoholic Steatohepatitis (NASH). We look forward to bringing you more insights on AI digital pathology from our guest speakers, so do stay tuned!Read More
Date: 14 Jul 2020
Catch this webinar on preclinical NASH, as Wuxi Apptec and HistoIndex share their experience in their efforts to determine the clinical relevance and translatability of NASH models and hepatic fibrosis in particular.Read More